全文获取类型
收费全文 | 196944篇 |
免费 | 2263篇 |
国内免费 | 256篇 |
专业分类
耳鼻咽喉 | 1584篇 |
儿科学 | 6896篇 |
妇产科学 | 3249篇 |
基础医学 | 20544篇 |
口腔科学 | 2078篇 |
临床医学 | 14071篇 |
内科学 | 34817篇 |
皮肤病学 | 1533篇 |
神经病学 | 18081篇 |
特种医学 | 10120篇 |
外科学 | 31416篇 |
综合类 | 2433篇 |
现状与发展 | 1篇 |
一般理论 | 5篇 |
预防医学 | 19035篇 |
眼科学 | 3156篇 |
药学 | 11352篇 |
中国医学 | 907篇 |
肿瘤学 | 18185篇 |
出版年
2023年 | 118篇 |
2022年 | 386篇 |
2021年 | 813篇 |
2020年 | 405篇 |
2019年 | 579篇 |
2018年 | 22467篇 |
2017年 | 17811篇 |
2016年 | 20123篇 |
2015年 | 1946篇 |
2014年 | 2053篇 |
2013年 | 2145篇 |
2012年 | 9010篇 |
2011年 | 22861篇 |
2010年 | 19841篇 |
2009年 | 12449篇 |
2008年 | 20772篇 |
2007年 | 22839篇 |
2006年 | 1597篇 |
2005年 | 3087篇 |
2004年 | 4140篇 |
2003年 | 5002篇 |
2002年 | 3062篇 |
2001年 | 822篇 |
2000年 | 863篇 |
1999年 | 540篇 |
1998年 | 343篇 |
1997年 | 308篇 |
1996年 | 166篇 |
1995年 | 188篇 |
1994年 | 152篇 |
1993年 | 100篇 |
1992年 | 176篇 |
1991年 | 229篇 |
1990年 | 228篇 |
1989年 | 194篇 |
1988年 | 151篇 |
1987年 | 145篇 |
1986年 | 115篇 |
1985年 | 114篇 |
1984年 | 81篇 |
1983年 | 78篇 |
1982年 | 62篇 |
1980年 | 69篇 |
1979年 | 50篇 |
1978年 | 57篇 |
1977年 | 45篇 |
1974年 | 49篇 |
1938年 | 60篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
Mitch Dowsett 《Breast cancer research and treatment》2004,87(1):11-18
cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple
tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational
research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the ‘Arimidex’,
Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with
clinical outcomes. In this study, adjuvant tamoxifen and anastrozole (‘Arimidex’) were compared alone and in combination in
more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival,
time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision,
local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program,
these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in
diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous
analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment
with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should
clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new
drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
993.
Objective: To study the gene polymorphisms of GSTT1 and GSTM1 in nasopharyngeal carcinoma (NPC) patients and controls in an
incidental area to evaluate the relationship between specific genotype and genotype combinations of these polymorphisms with
the risk of NPC. Methods: Cases and controls all came from the Southwestern Guangxi. DNAs were extracted from their WBC. PCR
technique was used to calculate the deletion rate of the two detoxific enzyme genes. Results: In this high risk area of NPC,
the residents had high level deletion rates of 47.4% (64/135) Ml and T1 40.7% (55/135). The deletion rates were even higher
in NPC patients, 61.5% (56/91) for Ml and 59.3% (54/91) for T1 respectively. There were statistical significances compared
with control,P<0.05 andP<0.01 for Ml and T1 respectively. The difference was more significant in terms of combined Ml and T1 deletion between patients
and controlsx
2=12.533,P=0.002. Conclusion: The combined deletion of detoxific enzyme genes GSTM1 and GSTT1 may be an important genetic susceptible
factor for NPC in Guangxi.
Biography: DENG Zhuo-lin (1929-), male, professor of pathology, Guangxi Medical University, majors in tumor pathology. E-mail :zhuolin@hotmail.com 相似文献
994.
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. 总被引:3,自引:2,他引:3
Y S Hong S Y Song S I Lee H C Chung S H Choi S H Noh J N Park J Y Han J H Kang K S Lee J Y Cho 《Annals of oncology》2004,15(9):1344-1347
BACKGROUND: Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer. This trial was conducted to evaluate the efficacy, safety and feasibility of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, with a view to replacing 5-fluorouracil (5-FU) in such patients. PATIENTS AND METHODS: Forty-four patients received capecitabine 1250 mg/m2 twice daily (2500 mg/m2/day) for 14 days followed by 7 days of rest, for up to six cycles. RESULTS: Capecitabine produced an objective response rate of 34% (all partial responses) and stable disease in 14 patients (30%). The median time to disease progression (TTP) was 3.2 months [95% confidence interval (CI) 2.7-6.4 months] and median overall survival was 9.5 months (95% CI 6.9-13.2 months). Hand-foot syndrome (HFS), nausea, anorexia, diarrhea and vomiting were the most common adverse events. While HFS was the most frequent grade 3/4 toxicity (National Cancer Institute Common Toxicity Criteria), only 9% of patients experienced grade 3 HFS. Severe myelosuppression was not reported during the study. CONCLUSIONS: Capecitabine monotherapy is active and well tolerated as first-line therapy in patients with advanced/metastatic gastric cancer. Larger comparative trials investigating capecitabine-based combination regimens in patients with advanced gastric cancer are warranted. 相似文献
995.
996.
Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning 总被引:5,自引:0,他引:5
Bingaman AW Waitze SY Alexander DZ Cho HR Lin A Tucker-Burden C Cowan SR Pearson TC Larsen CP 《Transplantation》2000,69(12):2491-2496
BACKGROUND: It has been hypothesized that regimens to induce transplantation tolerance and long-term hematopoietic chimerism require recipient conditioning with whole body irradiation or a cytoablative regimen to create space within the marrow microenvironment to permit pluripotent stem cell engraftment. The purpose of this study was to determine if transplantation of an intact bone marrow microenvironment in the form of a bone graft would permit stable hematopoietic stem cell engraftment, shape the repertoire of developing T cells, and induce donor-specific unresponsiveness in the absence of a conditioning regimen. METHODS: Fragments of femur were transplanted under the kidney capsule of recipient mice. At defined time points after bone graft transplantation recipients were assayed for chimerism, bone graft viability, and responses to donor and third party alloantigens in vitro and in vivo. RESULTS: In the absence of an immunological barrier, bone graft transplantation resulted in long-term multi-lineage hematopoietic chimerism in the peripheral blood. Nude bone graft transplantation into SCID recipients resulted in development of donor- derived T cells that underwent negative selection on bone graft derived I-E+ cells within the thymus. Across a fully allogeneic barrier in immunocompetent recipients treated with combined blockade of the CD40 and CD28 pathways bone graft transplantation resulted in long-term donor-specific hyporesponsiveness in vitro and acceptance of donor specific skin grafts. CONCLUSIONS: Transplantation of bone marrow in the form of a bone graft may facilitate the production of hematopoietic chimerism and lead to long-term donor-specific hyporesponsiveness in the absence of a cytoreductive conditioning regimen. 相似文献
997.
Background Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats. Furthermore, it is debated whether inhibition of gastric acid secretion may promote gastric carcinogenesis. In the present study we examined the combined effect of gastroduodenal reflux and acid inhibition with respect to the development of gastric carcinoma in the rat.Methods Following the construction of a gastrojejunostomy in male Wistar rats, half of them were given the proton pump inhibitor lanzoprazole for 1 year. The rats were then killed and the pH in the stomach and gastrin in blood were measured. The stomach was examined macroscopically as well as histologically.Results Gastrin levels at autopsy were significantly increased in treated rats compared to the control group, confirming an effect of lanzoprazole on gastric acid secretion. Body weight was significantly reduced in the treated rats. Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type. Gastric cancers occurred significantly more often in lanzoprazole-treated rats (50%) compared with controls (27%).Conclusion Lanzoprazole given orally enhances the carcinogenic effect of duodenogastric reflux in rats. 相似文献
998.
Hideki Nagano Shigekazu Ohyama Yoshihiro Sakamoto Keiichiro Ohta Toshiharu Yamaguchi Tetsuichiro Muto Akio Yamaguchi 《Gastric cancer》2004,7(1):54-59
Background Pylorus-preserving gastrectomy (PPG) and transverse gastrectomy (TrG) have been accepted as function-preserving procedures for node-negative early gastric cancer. It is believed that a better quality of life is guaranteed after PPG or TrG compared to that after distal subtotal gastrectomy (DSG) with Billroth type-I reconstruction. However, objective evaluations of the gastric remnant following gastrectomy have not been widely reported, and the real advantages and disadvantages of PPG or TrG over DSG remain unclear. Moreover, the risk of secondary cancer after PPG or TrG is uncertain.Methods Between 1991 and 2000, 834 DSGs were carried out in our institute for preoperatively diagnosed patients with early gastric cancer. The degree of residual gastritis and the amount of diet residue in the gastric remnant were evaluated by annual gastrointestinal endoscopic investigations prospectively for 72 patients after PPG, 95 patients after TrG, and 60 patients after DSG. These analyses were performed using the RGB classification (residue, gastritis, bile). The incidence of disease greater than or equal to grade 2 was calculated, and the time trends of the incidence for each procedure were also studied for 3 years after gastrectomy. In addition, secondary cancer cases in the gastric remnant mucosa were checked for each procedure during this period, and the incidence of secondary cancer after each operation was calculated.Results The incidence of gastritis, of grade 2 or more, found in the gastric remnant was significantly lower after PPG (1.4%) and TrG (2.1%) than after DSG (43.3%). However, the incidence of moderate or greater residue in the gastric remnant, grade 2 or more, was significantly higher after PPG (45.8%) and TrG (40.0%) than after DSG (11.7%). The analysis of time trends of gastritis and diet residue reflected the significant advantage or disadvantage for each procedure 1 year after surgery. The analysis also included these factors without consideration of elapsed time following surgery. Two patients after PPG (2.8%) and three patients after TrG (3.2%) developed secondary cancer in the gastric remnant. No DSG-treated patient showed new cancer genesis in the remaining stomach.Conclusion PPG and TrG have the advantage over DSG in preventing postoperative gastritis in the gastric remnant. On the other hand, moderate or greater diet residue in the gastric remnant is more common after PPG or TrG than after DSG. For the risk of carcinogenesis in the remnant gastric mucosa, we could not conclude that there was any apparent difference between these range-limited gastrectomies and conventional DSG. Further study is necessary to determine the significant advantages and disadvantages of using PPG or TrG. 相似文献
999.
Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer 总被引:3,自引:0,他引:3
Tadeusz Popiela Jan Kulig Antoni Czupryna Antoni M. Szczepanik Marek Zembala 《Gastric cancer》2004,7(4):240-245
Background Despite curative resection, 50%–90% of gastric cancer patients die of disease relapse. Although some clinical trials have indicated that chemotherapy and immunochemotherapy may be effective modalities, more recent studies have not been able to define the standard treatment for advanced gastric cancer. The present study evaluated the effect of adjuvant immunochemotherapy with the use of BCG (bacille Calmette-Guérin) and FAM (5-fluorouracil, adriamycin, mitomycin C) chemotherapy on the survival of patients with locally advanced resectable gastric cancer.Methods A total of 156 patients with stage III or IV gastric cancer who had undergone curative resection were randomly assigned to three treatment groups: BCG + FAM (immunochemotherapy), FAM (chemotherapy), and control (surgery only). Treatment was continued for 2 years or until death. Further postsurgical follow up was carried on for up to 10 years.Results Overall 10-year survival was 47.1% for the immunochemotherapy group (P < 0.037 vs FAM and P < 0.0006 vs control), 30% for the chemotherapy group (vs control, NS), and 15.2% for the control group. In patients with pT2/T3 primary tumors, 10-year survival was 55.3% for BCG + FAM vs 28.2% for FAM (P < 0.01) and 14.6% for the control group (P < 0.00018). BCG + FAM signifi-cantly improved the survival of patients with intestinal-type but not diffuse-type cancer. Immunochemotherapy was well tolerated.Conclusion This study, based on a limited number of patients, indicates that adjuvant immunochemotherapy (BCG + FAM) may prolong the survival of gastric cancer patients after curative gastrectomy; in particular, in patients with pT2/T3 tumors and intestinal-type primary tumors. There was no survival benefit from FAM adjuvant chemotherapy. 相似文献
1000.